Results 111 to 120 of about 142,623 (303)
Synthesis, Antiplatelet and Vasorelaxing Activities of Xanthone Derivatives
, 2010 A series of omega-aminoalkoxylxanthones was synthesized and tested in vitro for their ability to inhibit platelet aggregation and cause vasorelaxing action.
HUNG, CHI-FENG;SHIEH, BOR-JINN;YANG, SHYH-CHYUN;TENG, CHE-MING;LIN, CHUN-NAN +1 more
core
Clinical Pharmacology &Therapeutics, EarlyView.The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang +5 more
wiley +1 more source
PharmaceuticalsNon-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely utilized pharmaceuticals worldwide. Besides their recognized anti-inflammatory effects, these drugs exhibit various other pleiotropic effects in several cells, including platelets ...
Alexandros Tsoupras +5 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The optimal antithrombotic regimen for peripheral artery disease, balancing thromboembolic and bleeding risks, remains uncertain. This study aimed to compare the efficacy and safety of antithrombotic regimens in patients with peripheral artery
Yuriko Hiruma +9 more
doaj +1 more source
Antiplatelet drugs in cardiological practice: Established strategies and new developments
, 2008 Florian Krötz, Hae-Young Sohn, Volker KlaussCardiology, Medical Policlinic, Ludwig-Maximilians-Universität, Ziemssenstr. 1, 80336 MünchenAbstract: A common pathophysiological course in vascular diseases is an overwhelming activation and ...
Florian Krötz +2 more
core
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Antiplatelet agents in perioperative noncardiac surgeries: to maintain or to suspend?
, 2018 Juliana Maria Dantas Mendonça Borges,1,2,* Fernanda Oliveira de Carvalho,1,* Isla Alcântara Gomes,3,* Mario Borges Rosa,4,* Antonio Carlos Sobral Sousa1,* 1Nucleus of Post-Graduation in Health Sciences, Federal University of Sergipe, S ...
Borges JMDM +4 more
core
ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri +12 more
wiley +1 more source